Deulinoleate ethyl is under clinical development by Retrotope and currently in Phase II for Progressive Supranuclear Palsy. According to GlobalData, Phase II drugs for Progressive Supranuclear Palsy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Deulinoleate ethyl LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Deulinoleate ethyl overview

RT-001 is under development for the treatment of amyotrophic lateral sclerosis, progressive supranuclear palsy, infantile neuroaxonal dystrophy (INAD). The drug candidate is administered orally as a capsule. The drug candidate is a di-deuteron synthetic homolog of linoleic acid ethyl ester, an omega 6 polyunsaturated fatty acid and developed using transformational platform technology. It was also under development for Smith-Lemli-Opitz syndrome, Friedreich's ataxia, Alzheimer’s disease, Parkinson’s disease, neuronal ceroid lipofuscinosis like Batten disease, Huntington’s disease, age-related macular degeneration (AMD), diabetic retinopathy, amyotrophic lateral sclerosis, PLA2G6-associated neurodegeneration, Tay Sachs (LOTS), progressive supranuclear palsy and lung damage caused by COVID-19.

Retrotope overview

Retrotope is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases. The company is headquartered in Los Altos, California, the US.

For a complete picture of Deulinoleate ethyl’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.